Dr. Ta-Ching Chen, Associate Professor at NTU Hospital’s Department of Ophthalmology, is redefining how we tackle complex eye diseases. After completing advanced training in 2017 at Massachusetts Eye and Ear (MEE)—a global hub for innovative ophthalmic therapies—he brought back invaluable expertise to Taiwan.

At MEE, Dr. Chen witnessed the development of Luxturna, the first gene therapy for inherited retinal diseases. In 2021, he performed East Asia's first retinal gene therapy microsurgery, marking a groundbreaking achievement in ophthalmic care.

Now leading research into diagnostic and therapeutic models, Dr. Chen is paving the way for new treatments in the fight against challenging and rare eye conditions. His innovative systems are offering a brighter future for patients worldwide.

Follow #Globalbio to stay updated on the latest breakthroughs in eye care and medical innovation!
#OphthalmologyInnovation #GeneTherapy #EyeCareRevolution #TaiwanExcellence